Chiodini P G, Cozzi R, Dallabonzana D, Oppizzi G, Verde G, Petroncini M, Liuzzi A, del Pozo E
J Clin Endocrinol Metab. 1987 Mar;64(3):447-53. doi: 10.1210/jcem-64-3-447.
We studied the effects of acute and chronic sc administration of SMS 201-995 (SMS), a long-acting somatostatin analog, in acromegalic patients. The results were compared with those obtained in the same patients treated with oral bromocriptine (Brc). A single dose of 50 micrograms SMS administered to 28 patients induced a more rapid, greater, and more prolonged reduction in plasma GH levels than did 2.5 mg Brc. Chronic treatment [60-330 days; mean 208 +/- 23 (+/- SEM)] with SMS (100-300 micrograms/day) induced in 16 patients a significantly greater decrease in mean plasma GH and somatomedin-C levels than did 20 mg Brc. Combined treatment with the 2 agents had an additional effect. The clinical and metabolic parameters of acromegaly dramatically improved in all patients whose plasma GH and somatomedin-C levels decreased even if they were not normalized by SMS. Reduction in tumor size occurred in 3 of the 10 patients examined by computed tomography before and during SMS treatment. We conclude that SMS is more effective than Brc and that the 2 drugs may be complementary in the medical treatment of acromegaly.
我们研究了长效生长抑素类似物SMS 201-995（SMS）急性和慢性皮下注射对肢端肥大症患者的影响。将结果与同一批患者口服溴隐亭（Brc）治疗的结果进行比较。给28例患者单次注射50微克SMS，与2.5毫克Brc相比，能更快速、更显著且更持久地降低血浆生长激素（GH）水平。对16例患者进行SMS慢性治疗[60 - 330天；平均208±23（±标准误）]，剂量为100 - 300微克/天，与20毫克Brc相比，能使平均血浆GH和生长调节素-C水平显著降低更多。两种药物联合治疗有额外效果。所有血浆GH和生长调节素-C水平降低的患者，即使未被SMS恢复正常，肢端肥大症的临床和代谢参数也显著改善。在SMS治疗前和治疗期间接受计算机断层扫描检查的10例患者中，有3例肿瘤大小缩小。我们得出结论，SMS比Brc更有效，且这两种药物在肢端肥大症的药物治疗中可能具有互补性。
